Related Experiment Videos
JNK: a new therapeutic target for diabetes
Brydon L Bennett1, Yoshitaka Satoh, Alan J Lewis
1Celgene Corporation, 4550 Towne Centre Court, San Diego, CA 92121, USA. bbennett@celgene.com
Current Opinion in Pharmacology
|August 7, 2003
Summary
Jun N-terminal kinase (JNK) is crucial for immune responses but may also drive diabetes. Inhibiting JNK could offer new therapeutic strategies for metabolic diseases like obesity and insulin resistance.
Area of Science:
- Molecular Biology
- Immunology
- Metabolic Disease Research
Background:
- Jun N-terminal kinase (JNK) regulates the transcription factor AP-1, a key player in immune response gene expression.
- JNK inhibitors have been pursued for chronic inflammatory diseases.
- Emerging evidence links activated JNK to diabetes, insulin resistance, and obesity.
Purpose of the Study:
- To explore the role of activated Jun N-terminal kinase (JNK) in the development of diabetes.
- To investigate the mechanisms by which JNK signaling may promote metabolic dysfunction.
- To re-evaluate JNK as a therapeutic target beyond inflammatory conditions.
Main Methods:
- Review of genetic evidence linking JNK to metabolic disorders.
- Analysis of emerging pharmacological data on JNK activity.
- Exploration of stress-activated protein kinase pathways.
Main Results:
- Activated JNK signaling is implicated in the pathogenesis of diabetes.
- Multiple mechanisms suggest JNK's role in promoting insulin resistance and obesity.
- JNK's function extends beyond immune regulation to metabolic control.
Conclusions:
- Jun N-terminal kinase (JNK) plays a critical role in metabolic diseases, including diabetes, insulin resistance, and obesity.
- Targeting JNK may represent a novel therapeutic approach for these conditions.
- Further research is warranted to elucidate the multifaceted roles of JNK in health and disease.